Literature DB >> 7686817

Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens.

T Kageshita1, Z Wang, L Calorini, A Yoshii, T Kimura, T Ono, S Gattoni-Celli, S Ferrone.   

Abstract

Immunoperoxidase staining of frozen sections from surgically removed melanoma lesions showed that anti-human leukocyte antigen (HLA)-A2, A28 monoclonal antibody (mAb) stained keratinocytes, but did not stain melanoma cells in 21% of the 14 primary and 44% of the 9 metastatic lesions tested. The loss of HLA-A2 and/or A28 allospecificities did not affect the staining patterns with mAb recognizing monomorphic determinants of HLA Class I antigens, in terms of percentage of stained melanoma cells and intensity of staining. This finding is not likely to reflect the sensitivity of the immunoperoxidase technique, since cytofluorographic analysis detected no significant difference in the staining pattern by mAb to monomorphic determinants of HLA Class I antigens between a melanoma cell line and an autologous transfectant that had acquired HLA-A2 antigens following gene transfer. The results of the present study imply that the frequency of abnormalities in HLA Class I antigen expression by melanoma cells is higher than that described in the literature, since selective losses of HLA Class I allospecificities are not detected by staining of melanoma cells with mAb to monomorphic determinants of HLA Class I antigens. The latter reagents have been used in most of the published studies to characterize the expression of HLA Class I antigens in melanoma lesions. Furthermore, the present results provide a mechanism for the unexpected resistance to cytotoxic T-cell-mediated lysis and the unexpected poor clinical course of the disease in some patients despite a high expression of HLA Class I antigens as measured by staining of melanoma cells with mAb to monomorphic determinants.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7686817

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  13 in total

Review 1.  Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance.

Authors:  Robert L Ferris; Jennifer L Hunt; Soldano Ferrone
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

2.  Melanoma, immune surveillance, and immunotherapy.

Authors:  S Ferrone
Journal:  J Clin Invest       Date:  1994-04       Impact factor: 14.808

3.  Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.

Authors:  L Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; A Mixon; N P Restifo; S L Topalian; T B Simonis; S A Rosenberg
Journal:  Cancer Res       Date:  1995-07-15       Impact factor: 12.701

4.  Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.

Authors:  F M Marincola; P Shamamian; T B Simonis; A Abati; J Hackett; T O'Dea; P Fetsch; J Yannelli; N P Restifo; J J Mulé
Journal:  J Immunother Emphasis Tumor Immunol       Date:  1994-07

5.  Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells.

Authors:  Sonja Verheyden; Soldano Ferrone; Arend Mulder; Frans H Claas; Rik Schots; Barbara De Moerloose; Yves Benoit; Christian Demanet
Journal:  Cancer Immunol Immunother       Date:  2008-10-08       Impact factor: 6.968

6.  Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.

Authors:  N P Restifo; F M Marincola; Y Kawakami; J Taubenberger; J R Yannelli; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1996-01-17       Impact factor: 13.506

Review 7.  A novel post-transcriptional role for ubiquitin in the differential regulation of MHC class I allotypes.

Authors:  Florencia Cano; Paul J Lehner
Journal:  Mol Immunol       Date:  2012-11-07       Impact factor: 4.407

Review 8.  Vaccination for melanoma.

Authors:  L W Thompson; L Brinckerhoff; C L Slingluff
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.945

9.  Defective HLA class I antigen processing machinery in cancer.

Authors:  Lei Cai; Theodoros Michelakos; Teppei Yamada; Song Fan; Xinhui Wang; Joseph H Schwab; Cristina R Ferrone; Soldano Ferrone
Journal:  Cancer Immunol Immunother       Date:  2018-02-27       Impact factor: 6.968

10.  The RNA-binding E3 ubiquitin ligase MEX-3C links ubiquitination with MHC-I mRNA degradation.

Authors:  Florencia Cano; Helen Bye; Lidia M Duncan; Karine Buchet-Poyau; Marc Billaud; Mark R Wills; Paul J Lehner
Journal:  EMBO J       Date:  2012-08-03       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.